Cargando…

Characterization of the resting-state brain network topology in the 6-hydroxydopamine rat model of Parkinson’s disease

Resting-state functional MRI (rsfMRI) is an imaging technology that has recently gained attention for its ability to detect disruptions in functional brain networks in humans, including in patients with Parkinson’s disease (PD), revealing early and widespread brain network abnormalities. This method...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westphal, Robert, Simmons, Camilla, Mesquita, Michel B., Wood, Tobias C., Williams, Steve C. R., Vernon, Anthony C., Cash, Diana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382982/ https://www.ncbi.nlm.nih.gov/pubmed/28249008 http://dx.doi.org/10.1371/journal.pone.0172394

Ejemplares similares

Whole-brain ex-vivo quantitative MRI of the cuprizone mouse model
por: Wood, Tobias C., et al.
Publicado: (2016)

Mitochondrial Dynamics and Mitophagy in the 6-Hydroxydopamine Preclinical Model of Parkinson's Disease
por: Galindo, Maria F., et al.
Publicado: (2012)

Parkinson’s Disease and the Heart: Studying Cardiac Metabolism in the 6-Hydroxydopamine Model
por: Silva da Fonsêca, Victor, et al.
Publicado: (2023)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson’s Disease
por: Pišlar, Anja, et al.
Publicado: (2018)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Differences in brain pathological changes between rotenone and 6-hydroxydopamine Parkinson’s disease models
por: Liu, Lan-Xiang, et al.
Publicado: (2018)

Metabolomics and biochemical alterations caused by pleiotrophin in the 6-hydroxydopamine mouse model of Parkinson’s disease
por: Gramage, Esther, et al.
Publicado: (2022)

Intranasal delivery of mitochondria for treatment of Parkinson’s Disease model rats lesioned with 6-hydroxydopamine
por: Chang, Jui-Chih, et al.
Publicado: (2021)

Tissue optimization strategies for high‐quality ex vivo diffusion imaging
por: Barrett, Rachel L. C., et al.
Publicado: (2022)

Cognitive-Enhancing Effect of Quercetin in a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Sriraksa, Napatr, et al.
Publicado: (2012)

Treadmill exercise alleviates short-term memory impairment in 6-hydroxydopamine-induced Parkinson’s rats
por: Cho, Han-Sam, et al.
Publicado: (2013)

Expression of Tgfβ1 and Inflammatory Markers in the 6-hydroxydopamine Mouse Model of Parkinson’s Disease
por: Haas, Stefan Jean-Pierre, et al.
Publicado: (2016)

Impaired Voluntary Wheel Running Behavior in the Unilateral 6-Hydroxydopamine Rat Model of Parkinson's Disease
por: Pan, Qi, et al.
Publicado: (2015)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Transcriptome profiling of five brain regions in a 6‐hydroxydopamine rat model of Parkinson’s disease
por: Lyu, Ying, et al.
Publicado: (2021)

Changes in the Neuronal Architecture of the Hippocampus in a 6-Hydroxydopamine-Lesioned Rat Model of Parkinson Disease
por: Kim, Bohye, et al.
Publicado: (2022)

Neuroprotective Effect of Pseudoginsenoside-F11 on a Rat Model of Parkinson's Disease Induced by 6-Hydroxydopamine
por: Wang, Jian Yu, et al.
Publicado: (2013)

Neuroprotective Effect of Quercetin Nanocrystal in a 6-Hydroxydopamine Model of Parkinson Disease: Biochemical and Behavioral Evidence
por: Ghaffari, Fatemeh, et al.
Publicado: (2018)

Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson’s Disease Models
por: Yurchenko, Ekaterina A., et al.
Publicado: (2018)

Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease
por: Kubota, Maho, et al.
Publicado: (2020)

Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson’s Disease
por: Xicoy, Helena, et al.
Publicado: (2019)

Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats
por: Razaghi, Roghaieh, et al.
Publicado: (2021)

Lipid profiles in the cerebrospinal fluid of rats with 6-hydroxydopamine-induced lesions as a model of Parkinson’s disease
por: Qiu, Jiewen, et al.
Publicado: (2023)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

Amphiregulin blockade decreases the levodopa‐induced dyskinesia in a 6‐hydroxydopamine Parkinson's disease mouse model
por: Kambey, Piniel Alphayo, et al.
Publicado: (2023)

The dosage of curcumin to alleviate movement symptoms in a 6-hydroxydopamine-induced Parkinson's disease rat model
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Pharmacological, Biochemical and Immunological Studies on Protective Effect of Mangiferin in 6-Hydroxydopamine (6-OHDA)-Induced Parkinson’s Disease in Rats
por: Tiwari, Prafulla Chandra, et al.
Publicado: (2021)

Africanized Bee Venom (Apis mellifera Linnaeus): Neuroprotective Effects in a Parkinson’s Disease Mouse Model Induced by 6-hydroxydopamine
por: Dantas, Camila G., et al.
Publicado: (2022)

Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease
por: Thornton, Emma, et al.
Publicado: (2012)

Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
por: Shin, Keon Sung, et al.
Publicado: (2015)

Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson’s Disease
por: Farbood, Yaghoob, et al.
Publicado: (2015)

Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission
por: Vajdi-Hokmabad, Reza, et al.
Publicado: (2017)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

Tetramethylpyrazine Analogue T-006 Exerts Neuroprotective Effects against 6-Hydroxydopamine-Induced Parkinson's Disease In Vitro and In Vivo
por: Zhou, Hefeng, et al.
Publicado: (2019)

Preclinical Comparison of Stem Cells Secretome and Levodopa Application in a 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Teixeira, Fábio G., et al.
Publicado: (2020)

Probiotic Enhancement of Antioxidant Capacity and Alterations of Gut Microbiota Composition in 6-Hydroxydopamin-Induced Parkinson’s Disease Rats
por: Tsao, Shu-Ping, et al.
Publicado: (2021)

A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson’s Disease for the Study of Non-Motor Symptoms
por: Masini, Débora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_snv9u0hlvg2rop7i8n1c4m2iqv